Advertisement

Langenbeck's Archives of Surgery

, Volume 396, Issue 3, pp 313–321 | Cite as

Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases

  • Alessandro ZerbiEmail author
  • Vanessa Capitanio
  • Letizia Boninsegna
  • Claudio Pasquali
  • Guido Rindi
  • Gianfranco Delle Fave
  • Marco Del Chiaro
  • Riccardo Casadei
  • Massimo Falconi
  • AISP Network Study Group
Endocrine Surgery

Abstract

Background

Information on the treatment of pancreatic endocrine tumours (PETs) comes mostly from small, retrospective, uncontrolled studies.

Methods

Newly diagnosed, histologically proven PETs, observed from June 2004 to March 2007 in 24 Italian centres, were included in a specific dataset.

Results

Three-hundred and ten patients (mean age 57.6 years, females 46.6%) were analysed. At the time of recruitment, 262 (84.5%) underwent surgery. The percentage of operated patients was 91.9% and 62.0% in surgical and non-surgical centres, respectively. A curative resection was carried out in 83.6% (n = 219) of cases, a palliative resection (debulking) in 10.7% (n = 28), an exploratory laparotomy in 4.6% (n = 12), and a bypass procedure in 1.1% (n = 3). Laparoscopy was performed in 8.0% (n = 21) of cases. Resection consisted of a pancreatoduodenectomy in 46 cases (21.0%), a distal pancreatectomy in 95 (43.4%), an enucleation in 50 (22.8%), a middle pancreatectomy in 16 (7.3%) and a total pancreatectomy in 12 (5.5%). Liver resection was associated with pancreatic resection in 26 cases (9.9%). Post-operative mortality was 1.5% and morbidity 39.7%, respectively. A curative resection was performed more frequently in asymptomatic, small, non-metastatic, benign and at uncertain behaviour tumours, with low Ki67 values.

Conclusions

This study strongly indicates the fact that surgical resection represents the cornerstone treatment of PETs.

Keywords

Pancreatic endocrine tumours Pancreatic surgery Pancreatic resection 

Notes

Acknowledgements

The authors thank Monica Simonetti and Ennio Sarli of Centro Consulenze, Firenze, Italy, for their technical and statistical support. The study was partially supported by an unrestricted grant of IPSEN Italy.

Conflicts of interest

None.

References

  1. 1.
    Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID study group (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27(28):4656–4663, Epub 2009 Aug 24. PMID: 19704057; doi: 10.1200/JCO.2009.22.8510 PubMedCrossRefGoogle Scholar
  2. 2.
    Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28(1):69–76, Epub 2009 Nov 23. PMID: 19933912; doi: 10.1200/JCO.2009.24.2669 PubMedCrossRefGoogle Scholar
  3. 3.
    Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plöckinger U, Mallorca consensus conference participants, European Neuroendocrine Tumor Society (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2):214–219, PMID: 19713715; doi: 10.1159/000225952 PubMedCrossRefGoogle Scholar
  4. 4.
    Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G (2009) Peptide receptor therapies in neuroendocrine tumors. J Endocrinol Invest 32(4):360–369, Review. PMID: 19636207PubMedGoogle Scholar
  5. 5.
    Steward MJ, Warbey VS, Malhotra A, Caplin ME, Buscombe JR, Yu D (2008) Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics 28(4):1131–1145, PMID: 18635633; doi: 10.1148/rg.284075170 PubMedCrossRefGoogle Scholar
  6. 6.
    Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL, Fernández-Del Castillo C et al (2007) Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms. Arch Surg 142:347–354, PMID: 17438169; doi: 10.1001/archsurg.142.4.347 PubMedCrossRefGoogle Scholar
  7. 7.
    Kazanjian KK, Reber HA, Hines OJ (2006) Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141:765–770, PMID: 16924083; doi: 10.1001/archsurg.141.8.765 PubMedCrossRefGoogle Scholar
  8. 8.
    Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E (2002) Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13:614–621, PMID: 12056713PubMedCrossRefGoogle Scholar
  9. 9.
    Oberg K (2001) Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 12:111–114, PMID: 11762335CrossRefGoogle Scholar
  10. 10.
    Zeng XJ, Zhong SX, Zhu Y, Fei LM, Wu WJ, Cai LX (1988) Insulinoma: 31 years of tumor localization and excision. J Surg Oncol 39:274–278, PMID: 2848157PubMedCrossRefGoogle Scholar
  11. 11.
    Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, Chang R, Kleiner DE, Gorden P (2005) Malignant insulinoma: spectrum of unusual clinical features. Cancer 104:264–272, PMID: 15937909; doi: 10.1002/cncr.21179 PubMedCrossRefGoogle Scholar
  12. 12.
    Zerbi A, Falconi M, Rindi G, Fave GD, Tomassetti P, Pasquali C, Capitanio V, Boninsegna L, Di Carlo V. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010 Jan 19. [Epub ahead of print] PMID: 20087335; doi: 10.1038/ajg.2009.747
  13. 13.
    Heitz PU, Komminoth P, Perren A et al (2007) WHO histological classification of tumours of the endocrine pancreas. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and genetic of tumours of endocrine organs, 1st ed. IARC Press, Lyon, France. Am J Surg Pathol 31:1677–1682Google Scholar
  14. 14.
    Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401, PMID: 16967267PubMedCrossRefGoogle Scholar
  15. 15.
    Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J (2004) Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53:549–553, PMID: 15016750PubMedCrossRefGoogle Scholar
  16. 16.
    Eriksson B, Oberg K, Skogseid B (1989) Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 28:373–377, PMID: 2472825PubMedCrossRefGoogle Scholar
  17. 17.
    Halfdanarson TR, Rabe KG, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETS): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727–1733, PMID: 18515795; doi: 10.1093/annonc/mdn351 PubMedCrossRefGoogle Scholar
  18. 18.
    Oberg K (2004) Management of neuroendocrine tumours. Ann Oncol 15(Suppl 4):iv293–iv298, PMID: 15477324; doi: 10.1093/annonc/mdh942 PubMedGoogle Scholar
  19. 19.
    Akerstrom G, Hellman P (2007) Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21:87–109, PMID: 17382267; doi: 10.1016/j.beem.2006.12.004 PubMedCrossRefGoogle Scholar
  20. 20.
    Mabrut JY, Fernandez-Cruz L, Azagra JS, Bassi C, Delvaux G, Weerts J, Fabre JM, Boulez J, Baulieux J, Peix JL, Gigot JF, Hepatobiliary and pancreatic section (HBPS) of the Royal Belgian Society of Surgery, Belgian group for endoscopic surgery (BGES), Club Coelio (2005) Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 137:597–605, PMID: 15962401PubMedCrossRefGoogle Scholar
  21. 21.
    Fernández-Cruz L, Blanco L, Cosa R, Rendón H (2008) Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors? World J Surg 32:904–917, PMID: 18264824; doi: 10.1007/s00268-008-9467-2 PubMedCrossRefGoogle Scholar
  22. 22.
    Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL (1998) Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 2:472–482, PMID: 9843608PubMedCrossRefGoogle Scholar
  23. 23.
    Barakat MT, Meeran K (2004) Neuroendocrine tumours. Bloom SR Endocr Relat Cancer 11(1):1–18, PMID: 15027882CrossRefGoogle Scholar
  24. 24.
    Norton JA (2006) Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 10(3):327–331, PMID: 16504877; doi: 10.1016/j.gassur.2005.08.023 PubMedCrossRefGoogle Scholar
  25. 25.
    Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V, Pederzoli P (2010) Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010 Feb 17. [Epub ahead of print]. PMID: 20162460; doi: 10.1245/s10434-010-0949-8
  26. 26.
    Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, Pape UF, Ricke J, Goretzki PE, Wildi S, Steinmuller T, Oberg K, Scoazec JY, Frascati Consensus Conference, European Neuroendocrine Tumor Society (2006) Well-differentiated pancreatic non-functioning tumors/carcinoma. Neuroendocrinology 84:196–211, PMID: 17312380; doi: 10.1159/000098012 PubMedCrossRefGoogle Scholar
  27. 27.
    Crippa S, Bassi C, Warshaw AL, Falconi M, Partelli S, Thayer SP, Pederzoli P, Fernández-del Castillo C (2007) Middle pancreatectomy: indications, operative and long-term results. Ann Surg 246:69–76, PMID: 17592293; doi: 10.1097/01.sla.0000262790.51512.57 PubMedCrossRefGoogle Scholar
  28. 28.
    Aranha GV, Shoup M (2005) Nonstandard pancreatic resections for unusual lesions. Am J Surg 189:223–228, PMID: 15720996; doi: 10.1016/j.amjsurg.2004.11.005 PubMedCrossRefGoogle Scholar
  29. 29.
    Balzano G, Zerbi A, Veronesi P, Cristallo M, Di Carlo V (2003) Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg 20:506–510, PMID: 14506331PubMedCrossRefGoogle Scholar
  30. 30.
    Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC (1993) Non-functioning islet cell carcinoma of the pancreas. Surgery 114:1175–1181, PMID: 7903005PubMedGoogle Scholar
  31. 31.
    Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, Ajani JA, Wolff RA, Evans DB (2001) Non-functioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 130:1078–1085, PMID: 11742342; doi: 10.1067/msy.2001.118367 PubMedCrossRefGoogle Scholar
  32. 32.
    Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver; a plea for resection to increase survival. J Am Coll Surg 197:29–37, PMID: 12831921; doi: 10.1016/S1072-7515(03)00230-8 PubMedCrossRefGoogle Scholar
  33. 33.
    Hodul PJ, Strosberg JR, Kvols LK (2008) Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when it is indicated? Cancer Control 15:314–321, PMID: 18813199PubMedGoogle Scholar
  34. 34.
    Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M (2009) Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 41:49–55, PMID: 18209014; doi: 10.1093/annonc/mdm552 PubMedCrossRefGoogle Scholar
  35. 35.
    Ito H, Abramson M, Ito K, Swanson E, Cho N, Ruan DT, Swanson RS, Whang EE (2010) Surgery and staging of pancreatic neuroendocrine tumors: a 14-year experience. Gastrointest Surg 14(5):891–898, Epub 2010 Mar 12. PMID: 20224984; doi: 10.1007/s11605-010-1173-3 CrossRefGoogle Scholar
  36. 36.
    Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, Tanaka T, Nakachi K, Mitsunaga S, Kojima Y, Hagihara A, Hiraoka N (2010) Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol 40(4):313–318, Epub 2010 Jan 4. PMID: 20047862; doi: 10.1093/jjco/hyp173 PubMedCrossRefGoogle Scholar
  37. 37.
    Balzano G, Zerbi A, Capretti G, Rocchetti S, Capitanio V, Di Carlo V (2008) Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg 95:357–362, PMID: 17933001; doi: 10.1002/bjs.5982 PubMedCrossRefGoogle Scholar
  38. 38.
    van Heek NT, Kuhlmann KF, Scholten RJ, de Castro SM, Busch OR, van Gulik TM, Obertop H, Gouma DJ (2005) Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. Ann Surg 242:781–788, PMID: 16327488PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Alessandro Zerbi
    • 1
    Email author
  • Vanessa Capitanio
    • 2
  • Letizia Boninsegna
    • 3
  • Claudio Pasquali
    • 4
  • Guido Rindi
    • 5
  • Gianfranco Delle Fave
    • 6
  • Marco Del Chiaro
    • 7
  • Riccardo Casadei
    • 8
  • Massimo Falconi
    • 3
  • AISP Network Study Group
  1. 1.Pancreatic Surgery SectionHumanitas Scientific InstituteRozzano, MilanItaly
  2. 2.Pancreas Unit, Department of SurgerySan Raffaele Scientific InstituteMilanItaly
  3. 3.Department of SurgeryUniversity of Verona, Policlinico “GB Rossi”VeronaItaly
  4. 4.Department of SurgeryHospital of PaduaPaduaItaly
  5. 5.Department of PathologyCatholic University of RomeRomeItaly
  6. 6.Department of Medicine, II Clinica MedicaPoliclinico S. AndreaRomeItaly
  7. 7.Department of SurgeryCisanello HospitalPisaItaly
  8. 8.Department of SurgeryUniversity of Bologna, Sant’Orsola Malpighi HospitalBolognaItaly

Personalised recommendations